Kanseri ya porositate ni kanseri ya kabiri mu zikunze kugaragara ku bagabo ku isi, aho abagera kuri miliyoni 1.276 bashya bayanduye mu 2018, bangana na 7,1% by'abarwaye kanseri bose mu bagabo.
Imibare y'abahitanwa na kanseri ya porositate na yo iri hejuru, aho mu 2018 hapfuye abagera ku 37 005 ku isi.
Ariko, igipimo cy'impfu kiratandukanye cyane bitewe n'akarere, Afurika y'Iburengerazuba ifite ibyago byo gupfa kwa kanseri ya porositate ku mwanya wa gatanu ku isi, na Nijeriya ifite abaturage benshi n'ubukungu muri aka karere.
Muri Nijeriya, kanseri ya porositate ni kanseri ikunze kugaragara cyane kandi yica cyane ku bagabo, aho bivugwa ko ku bagabo 100.000 hapfa abagera kuri 32.8 n'abapfa 16.3.
Iki gipimo kiruta inshuro ebyiri igipimo cy'impfu muri Amerika y'Amajyaruguru.
Gutahura indwara bitinze, amikoro make yo gusuzuma no gutahura, hamwe no kugabanya inyandiko no gutanga raporo ku barwayi bigira uruhare mu gipimo cyo hejuru cy'impfu muri Nijeriya.
Muri Amerika, kanseri ya porositate ni yo mpamvu ya kabiri ikunze guhitana abagabo benshi bazira kanseri, aho abagabo bagera ku 40,0000 bapfa buri mwaka bazize iyi ndwara.
Umubare w'abahitanwa na kanseri ya porositate wagendaga ugabanuka buhoro buhoro kuva mu ntangiriro ya za 90, ariko iracyari ikibazo gikomeye cy'ubuzima.
Muri rusange, kanseri ya porositate ni indwara yica, cyane cyane mu turere dufite ubushobozi buke bwo kwivuza no gusuzuma.
Ariko, gutahura no kuvura hakiri kare bishobora gutuma habaho impinduka nziza cyane kandi bikagabanya impfu.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
["Buri gihe ujye usaba inama umuganga wawe cyangwa undi muntu wemewe mu bijyanye n'ubuzima ku bijyanye n'uburwayi. Ntuzigere wirengagiza inama z'abaganga cyangwa ngo utinde kuzisaba bitewe n'ikintu wasomye kuri uru rubuga. Niba utekereza ko ufite ikibazo cyihutirwa, hamagara 911 cyangwa ujye ku ivuriro rikwegereye. Nta mubano hagati y'umuganga n'umurwayi ukorwa n'uru rubuga cyangwa ikoreshwa ryarwo. Yaba BioMedLib cyangwa abakozi bayo, cyangwa undi muntu wese wagize uruhare kuri uru rubuga, nta gihamya batanga, yaba igaragara cyangwa itagaragara, ku bijyanye n'amakuru atangwa hano cyangwa ikoreshwa ryayo."]
["Ibirego: uburenganzira bw'umuhanzi"]
["Itegeko ryo mu 1998 ryerekeye uburenganzira bw'ibihumbi by'ibihumbi by'ibihumbi by'ibihumbi, 17 U.S.C. § 512 (DMCA) ritanga ubujurire ku bafite uburenganzira bw'umuhanzi bemera ko ibintu bigaragara kuri interineti bibangamira uburenganzira bwabo hakurikijwe amategeko y'uburenganzira bw'umuhanzi muri Amerika. "]
['Niba wemera ko ibintu cyangwa ibikoresho byashyizwe ku rubuga rwacu cyangwa serivisi bitubahiriza uburenganzira bwawe, wowe (cyangwa umuhagarariye) ushobora kutwoherereza ubutumwa udusaba ko ibyo bintu cyangwa ibikoresho bikurwaho, cyangwa ko utabikoresha.']
['Itangazo rigomba koherezwa mu nyandiko kuri interineti (reba ahanditse "Kwitaba" kugira ngo ubone aderesi ya interineti). ']
["DMCA isaba ko imenyesha ryawe ry'ikirego cyo kuvutswa uburenganzira rikubiyemo amakuru akurikira: (1) ibisobanuro by'igikorwa kirengera uburenganzira bw'umuhanzi kivugwaho kuvutswa uburenganzira; (2) ibisobanuro by'ibikubiyemo bivugwa ko ari ukurenga ku mategeko n'amakuru ahagije atuma dushobora kubona ibikubiyemo; (3) amakuru yo kuguhamagaraho, harimo aderesi yawe, nomero ya terefone na aderesi imeyiri; (4) inyandiko yawe ivuga ko ufite icyizere ko ibikubiyemo mu buryo bwatanzwe nta burenganzira bifite na nyiri uburenganzira bw'umuhanzi, cyangwa umukozi we, cyangwa mu mategeko ayo ari yo yose; "]
["(5) inyandiko yawe isinyweho, uhanishwa kubeshya, yemeza ko amakuru ari mu itangazo ari ukuri kandi ko ufite ububasha bwo kurengera uburenganzira bw'umuhanzi uvugwaho kubwamburwa; "]
["kandi (6) umukono usanzwe cyangwa wa elegitoroniki w'ufite uburenganzira ku nyandiko cyangwa uw'umuntu wabiherewe uburenganzira bwo gukora mu izina ry'ufite uburenganzira ku nyandiko. "]
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Kubijyanye']
["BioMedLib ikoresha mudasobwa zikoresha ikoranabuhanga mu gukora ibibazo n'ibisubizo."]
["Twatangiriye ku bitabo bya siyansi bivuga iby'ubuvuzi bigera kuri miriyoni 35 byo mu nkoranyamagambo yitwa PubMed/Medline."]
['Reba "Inyandiko z\'ibanze" na "Inyandiko y\'ibanze".']
